Vir Biotechnology Inc. (VIR) Misses Q3 EPS by 33c, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts VIR Hot Sheet
Join SI Premium – FREE
Vir Biotechnology Inc. (NASDAQ: VIR) reported Q3 EPS of ($1.17), $0.33 worse than the analyst estimate of ($0.84). Revenue for the quarter came in at $240 thousand versus the consensus estimate of $2.11 million.
2025 Financial Guidance
Based on current operating plans, the Company expects its cash, cash equivalents and investments to fund operations into mid-2027.
For earnings history and earnings-related data on Vir Biotechnology Inc. (VIR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- FDA approves first once-weekly insulin for type 2 diabetes mellitus in pediatric patients
- Meta's Muse AI to counter China models with subscribers, not ads, Alexandr Wang says - Nikkei
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
